Heart, Stroke Care For Disadvantaged Minorities
UCLA has been awarded a four-year, $3.89 million grant from the American Heart Association to establish a new research center focused on improving the health of disadvantaged minority patients at risk for stroke and heart attack. In addition to training future scientists, the center will collaborate with community partners on two studies exploring how to prevent stroke survivors from suffering a second stroke.
Monday, April 20, 2009
New Data On Highly Effective Treatment For Chronic Rhinosinusitis Presented By OptiNose
New Data On Highly Effective Treatment For Chronic Rhinosinusitis Presented By OptiNose
OptiNose has announced important new results from a Phase II trial of its novel nasal drug delivery device with fluticasone for the treatment of chronic rhinosinusitis. Patients in the active treatment group experienced significant improvements in nasal symptoms, nasal discomfort and sense of smell. There was also a highly significant and progressive reduction in nasal swelling.
OptiNose has announced important new results from a Phase II trial of its novel nasal drug delivery device with fluticasone for the treatment of chronic rhinosinusitis. Patients in the active treatment group experienced significant improvements in nasal symptoms, nasal discomfort and sense of smell. There was also a highly significant and progressive reduction in nasal swelling.
Subscribe to:
Posts (Atom)
